Relmada Therapeutics (RLMD): Analysts See +181% Upside to $12 Target

Key Takeaways

• The central target of $12 is the arithmetic mean of five verifiable analyst price targets, with the most recent closing price near $4.27 implying a required upside of roughly 181%.
• The analyst range is wide, from a low of $8 to a high of $19, reflecting the binary, event-driven risk typical of a clinical-stage biotech.
• Relmada's bull case rests on NDV-01, its lead program for non-muscle invasive bladder cancer, and a cash runway management says extends into 2029.
• The biggest risks are a pre-revenue business model, execution on manufacturing and the investigational new drug (IND) filing, and potential future dilution.
• Because targets are spread so widely, the $12 figure is a statistical midpoint, not a promise or a consensus guarantee.
• Upcoming catalysts include third-quarter results and progress toward the NDV-01 IND filing, both expected near year-end.

Breaking Down the Analyst Targets

Relmada Therapeutics, Inc. (RLMD) is a clinical-stage biotechnology company headquartered in Coral Gables, Florida. Five individually verifiable analyst price targets were reviewed. The low is $8 (Leerink Partners, upgraded to Outperform in January 2026), followed by $9 (Jefferies, initiating coverage with a Buy in December 2025), $12 from both Piper Sandler (Kelsey Goodwin) and H.C. Wainwright (Andres Maldonado), and a high of $19 from Mizuho (Uy Ear), raised from $10 in March 2026.

These five targets average exactly $12.00, the central target used here. The roughly $8-to-$19 spread is unusually wide and underscores genuine disagreement. Mizuho's top-of-range view cites "better than expected" 12-month durability data strengthening conviction in NDV-01's "best-in-class potential," while lower targets weigh the same clinical program more conservatively against binary execution risk. There is no official published consensus figure to which the $12 mean can be matched; it is a calculated average, not a forecast or a recommendation. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

From Current Price to the $12 Goal

With shares near $4.27 after a double-digit single-day gain, reaching $12 requires a rise of about 181%. By any standard, that is a very large move for an equity, though large percentage gaps are common among pre-revenue biotechs where a single clinical readout can re-rate the entire valuation. Relmada generated no product revenue and posted a trailing-twelve-month net loss of roughly $62 million, with negative EPS (earnings per share). Its roughly $218 million in cash and equivalents at mid-2026 is expected by management to fund operations through 2029. The path to $12 therefore depends less on near-term financials and more on clinical and regulatory milestones for NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel being developed for non-muscle invasive bladder cancer, alongside the earlier-stage sepranolone program.

What Could Support a Move Toward the Target

The primary support is clinical data. NDV-01 has reported strong complete-response and durability results in Phase 2, which analysts including Mizuho have cited in raising targets. A cleared IND filing and initiation of the Phase 3 registrational program, targeted around year-end, would be a key de-risking step. A clean balance sheet that extends the runway reduces near-term dilution pressure, while management's engagement with institutional investors and recent insider activity signal confidence. In the biotech sector more broadly, positive data catalysts can compress valuations upward rapidly for small-cap names.

What Could Prevent the Target From Being Reached

The counterweight is equally real. Relmada has no commercial product, and its valuation rests almost entirely on future clinical success. Delays in GMP (Good Manufacturing Practice) manufacturing, an IND filing slip, or a Phase 3 design or efficacy disappointment could sharply reduce the stock's perceived value. A wide bid-ask spread and low average volume reflect limited liquidity, which amplifies volatility. Future capital raises could dilute shareholders, and the stock's own history—shares fell below $1 in late 2024 after prior depression-program failures—shows how quickly a biotech thesis can reset.

Technical Levels and Market Structure

The stock's 52-week range runs from roughly $2.15 to $8.00. The $8 area stands out as a meaningful resistance level, representing the recent high, while the low-$2 zone is the major support level. A psychological level near $5 sits between the current price and the prior high. Because the central target of $12 is well above the existing 52-week high, reaching it would require not just a rally but a breakout into entirely new price territory—consistent with a scenario where a pivotal clinical or regulatory milestone re-rates the shares.

Time Horizon and What Investors Should Monitor

Analyst price targets are typically set on a roughly 12-month research horizon, though individual firms do not always publish identical timeframes. The most relevant items to monitor are the IND filing for NDV-01 and the planned Phase 3 program, expected near year-end 2026; third-quarter results scheduled for mid-November; manufacturing progress; any additional durability data; and analyst revisions following these events. Cash position, share-count changes, and sepranolone's proof-of-concept progress round out the watch list. No definitive outcome or timing should be assumed. From what I see, this is important because upcoming events could shift the probability weighting across those wide target ranges.

Using AI Tools for Ongoing Monitoring

For traders seeking a systematic way to track evolving conditions, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. I find this helpful when following names like RLMD where catalysts can move quickly. The tool is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening. In my view, it adds a layer of discipline to the research process without replacing fundamental analysis.

Final Assessment

The $12 central target is a calculated average of five verifiable analyst price targets ranging from $8 to $19, not an official consensus or a forecast. From a price near $4.27, it implies a roughly 181% move—a very large step that hinges almost entirely on clinical and regulatory execution. The strongest supports are encouraging NDV-01 durability data and a long cash runway; the principal obstacles are a pre-revenue profile, manufacturing and IND timing, and dilution risk. With targets this far apart, the spread itself is the message: analysts agree on potential but differ sharply on probability. What investors monitor next—the IND filing, Phase 3 initiation, and quarterly updates—will determine whether the stock builds a credible path toward that level.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Notable companies

Industry description

Market Cap

High and low price notable news

Volume